Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD - PubMed
- ️Sat Jan 01 2022
Review
Novel and Promising Strategies for Therapy of Post-Transplant Chronic GVHD
Irina Kostareva et al. Pharmaceuticals (Basel). 2022.
Abstract
Despite the achievements that have increased viability after the transplantation of allogeneic hematopoietic stem cells (aHSCT), chronic graft-versus-host disease (cGVHD) remains the main cause of late complications and post-transplant deaths. At the moment, therapy alternatives demonstrate limited effectiveness in steroid-refractory illness; in addition, we have no reliable data on the mechanism of this condition. The lack of drugs of choice for the treatment of GVHD underscores the significance of the design of new therapies. Improved understanding of the mechanism of chronic GVHD has secured new therapy goals, and organized diagnostic recommendations and the development of medical tests have ensured a general language and routes for studies in this field. These factors, combined with the rapid development of pharmacology, have helped speed up the search of medicines and medical studies regarding chronic GVHD. At present, we can hope for success in curing this formidable complication. This review summarizes the latest clinical developments in new treatments for chronic GVHD.
Keywords: graft-versus-host disease; hematopoietic stem cell transplantation; novel agents; oligosaccharides.
Conflict of interest statement
The authors declare no conflict of interest.
Figures

Relationship between aGVHD and cGVHD pathogenesis.

Structures of active components of the drugs currently used for the treatment of GVHD or in drug candidates under development.

Two types of homofucose backbone chains in brown seaweed fucoidans (R depicts the places of potential attachment of carbohydrate substituents, sulfate, and acetyl groups) and the structure of fucoidan CF from C. flagelliformis seaweed.

The main structural features of fucosylated chondroitin sulfates from the sea cucumbers Massinium magnum, Apostichopus japonicus, Holothuria hilla, and Hemioedema spectabilis, as examples of natural polysaccharides of this type.
Similar articles
-
Evolving Therapeutic Options for Chronic Graft-versus-Host Disease.
Gonzalez RM, Pidala J. Gonzalez RM, et al. Pharmacotherapy. 2020 Aug;40(8):756-772. doi: 10.1002/phar.2427. Epub 2020 Jun 15. Pharmacotherapy. 2020. PMID: 32441379 Review.
-
Carnevale-Schianca F, Caravelli D, Gallo S, Coha V, D'Ambrosio L, Vassallo E, Fizzotti M, Nesi F, Gioeni L, Berger M, Polo A, Gammaitoni L, Becco P, Giraudo L, Mangioni M, Sangiolo D, Grignani G, Rota-Scalabrini D, Sottile A, Fagioli F, Aglietta M. Carnevale-Schianca F, et al. Biol Blood Marrow Transplant. 2017 Mar;23(3):459-466. doi: 10.1016/j.bbmt.2016.12.636. Epub 2016 Dec 27. Biol Blood Marrow Transplant. 2017. PMID: 28039079 Clinical Trial.
-
Extracorporeal photopheresis in the management of graft-versus-host disease.
Bredeson C, Rumble RB, Varela NP, Kuruvilla J, Kouroukis CT; Stem Cell Transplant Steering Committee. Bredeson C, et al. Curr Oncol. 2014 Apr;21(2):e310-25. doi: 10.3747/co.21.1882. Curr Oncol. 2014. PMID: 24764713 Free PMC article.
-
Novel targets in the treatment of chronic graft-versus-host disease.
Im A, Hakim FT, Pavletic SZ. Im A, et al. Leukemia. 2017 Mar;31(3):543-554. doi: 10.1038/leu.2016.367. Epub 2016 Nov 30. Leukemia. 2017. PMID: 27899803 Review.
Cited by
-
Mougeot JC, Beckman MF, Hovan AJ, Hasséus B, Legert KG, Johansson JE, von Bültzingslöwen I, Brennan MT, Bahrani Mougeot F. Mougeot JC, et al. Support Care Cancer. 2023 Sep 21;31(10):587. doi: 10.1007/s00520-023-08044-3. Support Care Cancer. 2023. PMID: 37731134 Free PMC article.
-
Treatment of steroid-refractory graft versus host disease in children.
Gottardi F, Leardini D, Muratore E, Baccelli F, Cerasi S, Venturelli F, Zanaroli A, Belotti T, Prete A, Masetti R. Gottardi F, et al. Front Transplant. 2023 Sep 15;2:1251112. doi: 10.3389/frtra.2023.1251112. eCollection 2023. Front Transplant. 2023. PMID: 38993897 Free PMC article. Review.
-
Rosenstein RK, Rose JJ, Brooks SR, Tsai WL, Gadina M, Pavletic SZ, Nagao K, Cowen EW. Rosenstein RK, et al. JID Innov. 2023 Dec 7;4(2):100246. doi: 10.1016/j.xjidi.2023.100246. eCollection 2024 Mar. JID Innov. 2023. PMID: 38357212 Free PMC article.
References
-
- Carreras E., Diaz-Ricart M. The EBMT Handbook. Volume 3. Springer; Cham, Switzerland: 2018. Early Complications of Endothelial.
-
- Filipovich A.H., Weisdorf D., Pavletic S. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol. Blood Marrow Transpl. 2005;11:945–956. doi: 10.1016/j.bbmt.2005.09.004. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources